A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer

Tumor mutational burden (TMB) has been reported to determine the response to immunotherapy, thus affecting the patient’s prognosis in many cancers. However, it is unclear whether TMB or TMB-related signature could be used as prognostic indicators for ovarian cancer (OC), as its potential association...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Haoyu, Liu, Jingchun, Yang, Jiang, Wang, Zhi, Zhang, Zihui, Peng, Jiaxin, Wang, Ying, Hong, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393426/
https://www.ncbi.nlm.nih.gov/pubmed/36003381
http://dx.doi.org/10.3389/fimmu.2022.943389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393426/
https://www.ncbi.nlm.nih.gov/pubmed/36003381
http://dx.doi.org/10.3389/fimmu.2022.943389

Ejemplares similares